"Picibanil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.
| Descriptor ID |
D010844
|
| MeSH Number(s) |
D20.215.659
|
| Concept/Terms |
OK-432- OK-432
- OK 432
- OK432
- Streptococcal Preparation OK-432
- Streptococcal Preparation OK 432
- Streptococcal Preparation OK432
- Streptococcal OK-432
- Streptococcal OK 432
- Streptococcal OK432
|
Below are MeSH descriptors whose meaning is more general than "Picibanil".
Below are MeSH descriptors whose meaning is more specific than "Picibanil".
This graph shows the total number of publications written about "Picibanil" by people in this website by year, and whether "Picibanil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Picibanil" by people in Profiles.
-
OK432 versus doxycycline for treatment of macrocystic lymphatic malformations. Ann Otol Rhinol Laryngol. 2014 Feb; 123(2):81-8.
-
Intracavitary administration of OK-432 with subcutaneous priming for malignant ascites in a case of advanced renal cell carcinoma. Int J Urol. 2002 Jan; 9(1):57-9.
-
Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother. 1997 May; 44(3):137-49.
-
Inhibition of in vitro LAK generation by OK-432. Cancer Immunol Immunother. 1986; 23(3):207-13.
-
Immunotherapy of superficial bladder cancer. J Urol. 1982 Nov; 128(5):891-4.